Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
Vyome Biosciences’ management team members are the leaders in the field, with deep expertise, demonstrated capability and a proven track record of successfully launching over 50 products in dermatology & other life sciences areas, and building visionary companies.
Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The lead molecule (VB 1953), which targets the huge unmet need in the drug resistant Acne prescription market, will soon be entering the clinical phase as USFDA recently accepted Vyome's Investigational New Drug Application.
Vyome has state-of-the-art infrastructure facilities to carry out all its research and lab development work, with full-fledged formulation, analytical, chemistry, biology & molecular biology, clinical and the regulatory divisions. The infrastructure and the team enables Vyome to conceive ideas, develop them and commercialize them at a rapid pace.